# Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors

> **NCT06941766** · PHASE1,PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Intermediate Trophoblastic Tumor

## Interventions

- **DRUG:** QL1706
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06941766
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2027-04-16
- **Final completion:** 2028-04-16
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-04-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06941766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06941766, "Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06941766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*